SR-18662 is an optimized anticancel agent based on ML264. Treatment with SR-18662 has been shown to significantly slow the growth and division of colorectal cancer cells. The effect of SR-18662 at the same dose was greater than that of ML264 in terms of significantly inhibiting the growth of mice xenografts.
Physicochemical Properties
| Molecular Formula | C16H19CL2N3O4S |
| Molecular Weight | 420.3108 |
| Exact Mass | 419.047 |
| Elemental Analysis | C, 45.72; H, 4.56; Cl, 16.87; N, 10.00; O, 15.23; S, 7.63 |
| CAS # | 2505001-62-5 |
| Related CAS # | 2505001-62-5 |
| PubChem CID | 146674222 |
| Appearance | White to off-white solid powder |
| LogP | 1.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 26 |
| Complexity | 642 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | CS(=O)(=O)N1CCN(CC1)C(=O)CNC(=O)/C=C/C2=CC(=C(C=C2)Cl)Cl |
| InChi Key | WUJBXFXHDUVSFM-HWKANZROSA-N |
| InChi Code | InChI=1S/C16H19Cl2N3O4S/c1-26(24,25)21-8-6-20(7-9-21)16(23)11-19-15(22)5-3-12-2-4-13(17)14(18)10-12/h2-5,10H,6-9,11H2,1H3,(H,19,22)/b5-3+ |
| Chemical Name | (E)-3-(3,4-dichlorophenyl)-N-[2-(4-methylsulfonylpiperazin-1-yl)-2-oxoethyl]prop-2-enamide |
| Synonyms | SR-18662; SR 18662; SR18662 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | KLF5 (IC50 = 4.4 nM) |
| ln Vitro |
SR18662 (0-10 μM; 24-72 hours) significantly lessens CRC cell growth and proliferation when compared to ML264 , the vehicle control. It demonstrates improved effectiveness in lowering the viability of various CRC cell lines[1]. SR18662 (10 μM; 24-72 hours) shows a significant increase in the quantity of apoptotic cells in the DLD-1 and HCT116 cells in both the early and late states[1]. SR18662 (1 μM; 72 hours) reduces the expression of cyclins (cyclins E, A2, and B1), as well as elements of the MAPK (p-Erk) and WNT signaling pathways (p-GSK3 β) in cellular expression[1]. |
| ln Vivo | SR18662 (intraperitoneal injection; 5-10 mg/kg; daily or twice daily; 5 days injection, days break, and 5 days) significantly slows the growth of tumors in a mouse xenograft model[1]. |
| Animal Protocol |
Nude mice with DLD-1 cells[1] 5 mg/kg; 10 mg/kg; 25 mg/kg Intraperitoneal injection; 5mg/kg daily, 5mg/kg twice a day,10 mg/kg daily, 10 mg/kg twice per day, 25mg/kg daily, and 25 mg/kg twice per day; 5 days of injections, 2 days break, and 5 days of injections |
| References |
[1]. The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitroand In Vivo.Mol Cancer Ther.2019 Nov;18(11):1973-1984. |
Solubility Data
| Solubility (In Vitro) | DMSO: 84~125 mg/mL (199.9~297.4 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (4.95 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3792 mL | 11.8960 mL | 23.7920 mL | |
| 5 mM | 0.4758 mL | 2.3792 mL | 4.7584 mL | |
| 10 mM | 0.2379 mL | 1.1896 mL | 2.3792 mL |